Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IOBT 
IO Biotech Inc (IOBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9
1 Year Target Price $9
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.24% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 104.09M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 5 | Beta 0.44 | 52 Weeks Range 0.66 - 2.79 | Updated Date 08/29/2025 |
52 Weeks Range 0.66 - 2.79 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.37 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -80.63% | Return on Equity (TTM) -212.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84316844 | Price to Sales(TTM) - |
Enterprise Value 84316844 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 65880900 | Shares Floating 34636891 |
Shares Outstanding 65880900 | Shares Floating 34636891 | ||
Percent Insiders 0.36 | Percent Institutions 63.84 |
Upturn AI SWOT
IO Biotech Inc
Company Overview
History and Background
IO Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies to treat cancer. Founded with a vision to harness the power of the immune system to fight cancer, IO Biotech has developed a proprietary platform to identify and develop novel immunotherapeutic approaches.
Core Business Areas
- T-winu00ae Platform: IO Biotech's core platform technology, T-winu00ae, focuses on developing therapies that target immunosuppressive mechanisms in the tumor microenvironment (TME). This platform aims to reprogram immune cells within the tumor to promote anti-tumor activity.
- Clinical Development Programs: The company's primary business activity revolves around the clinical development of its lead product candidates, including IO102 and IO103, which are designed to target IDO and PD-L1, respectively, within the TME.
Leadership and Structure
IO Biotech Inc. has a management team led by CEO Mai-Britt Zocca. The organizational structure comprises research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- IO102 (IDO inhibitor): IO102 is an IDO (indoleamine 2,3-dioxygenase) inhibiting product candidate under clinical development. Market share data is not yet available as it is still in development. Competitors include companies developing IDO inhibitors and other immunotherapies. Major competitors include Bristol Myers Squibb, Merck, and Incyte, which formerly had Epacadostat, an IDO1 inhibitor, in development.
- IO103 (PD-L1 inhibitor): IO103 is a PD-L1 targeting product candidate under clinical development. Market share data is not yet available as it is still in development. Competitors include companies developing PD-L1 and PD-1 inhibitors. Major competitors include Merck (Keytruda), Bristol Myers Squibb (Opdivo), and Roche (Tecentriq).
Market Dynamics
Industry Overview
The immune-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by the increasing understanding of the role of the immune system in cancer development and progression. The market is characterized by intense competition and significant investment in research and development.
Positioning
IO Biotech Inc. aims to position itself as a leader in developing novel immunotherapies targeting the tumor microenvironment. Its T-winu00ae platform offers a unique approach to reprogram immune cells within the tumor, potentially leading to more effective cancer treatments.
Total Addressable Market (TAM)
The global immunotherapy market is estimated to be billions of dollars and is still growing. IO Biotech Inc. is positioned to capture a portion of this TAM by developing new innovative treatments targeting cancer. The TAM for the indications they are targeting is estimated in excess of $100Billion.
Upturn SWOT Analysis
Strengths
- Proprietary T-winu00ae platform for developing novel immunotherapies
- Strong focus on targeting the tumor microenvironment
- Clinical-stage product candidates with promising early results
- Experienced management team
Weaknesses
- Reliance on clinical trial results for future success
- High research and development costs
- Limited commercial infrastructure
- Dependence on partnerships for commercialization
Opportunities
- Expanding the T-winu00ae platform to new cancer targets
- Partnering with larger pharmaceutical companies for clinical development and commercialization
- Securing regulatory approvals for lead product candidates
- Addressing unmet medical needs in cancer treatment
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- PFE
- GILD
Competitive Landscape
IO Biotech's advantage lies in its T-winu00ae platform. Disadvantages include being a smaller player compared to large pharmaceutical companies with established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited to clinical trial advancements and fundraising activities.
Future Projections: Future growth depends on the successful clinical development and commercialization of its product candidates. Analyst projections are unavailable without specific market data and financial forecasts.
Recent Initiatives: Recent initiatives include advancing clinical trials for IO102 and IO103, exploring new partnerships, and expanding the T-winu00ae platform.
Summary
IO Biotech is a clinical-stage company developing immunotherapies with a promising platform. The company's success hinges on positive clinical trial outcomes and regulatory approvals. Significant risks remain, primarily due to competition and the challenges of drug development. Partnerships will be critical to the company's future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IO Biotech Inc. website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and does not constitute investment advice. Market share data are estimates and may vary. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IO Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | Founder, President, CEO, Principal Financial Officer & Director Dr. Mai-Britt Zocca Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.iobiotech.com |
Full time employees 78 | Website https://www.iobiotech.com | ||
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.